Microbial Fermentation CMO Market Size is Anticipated to Reach USD 9.6 Billion by 2035 | Roots Analysis

According to a recently published report by Roots Analysis, given the rising demand for cost-effective bioproduction, increasing adoption of microbial systems for recombinant proteins and enzymes, and the need to accelerate scale-up and commercialization timelines, the microbial fermentation CMO market is well positioned for future growth.

Microbial Fermentation CMO Market Overview

The global microbial fermentation CMO market is expected to reach USD 9.6 billion by 2035, growing at a CAGR of 9.4% during the forecast period till 2035.

Biopharmaceuticals represent one of the key therapeutic modalities in the modern healthcare industry, given their therapeutic potential and favorable safety profiles. Driven by several blockbuster products and burgeoning pipeline, biologics have become a key focus area for stakeholders in the pharmaceutical industry. To realize this therapeutic potential on a scale, the manufacturing of biologics, such as proteins, peptides, antibodies, enzymes, hormones and growth factors require an appropriate expression system. Notably, several types of microbes have been identified as versatile biomolecule expression systems. This can be attributed to the robustness of these microbial cell lines (compared to cells of higher eukaryotes), rendering them a popular choice for biopharmaceutical manufacturing.

Browse ~145 figures and ~165 market data tables spread across 335+ pages and detailed Table of Content on “Global Microbial Fermentation CMO market, till 2035 by Type of Expression System (Bacterial Expression Systems, Yeast Expression Systems and Other Expression Systems), Type of Biologic Manufactured (Recombinant Proteins, Enzymes, Plasmid DNA, Antibodies and Other Biologics), Company Size (Small, Mid-sized, and Large and Very Large Companies), End User (Pharmaceutical and Biotechnological Companies, and Academic and Research Institutes) and Key Geographical Regions (North America, Europe, Asia-Pacific and Rest of the World)” here: https://www.rootsanalysis.com/reports/microbial-fermentation-cmo-market.html

Market Drivers

Several factors are propelling the growth of global microbial fermentation CMO market. Rising demand for biopharmaceuticals, especially in areas like oncology, immunology, and rare diseases, is driving increased reliance on microbial fermentation CMOs due to limited in-house capabilities. Further, outsourcing offers significant cost savings and faster time-to-market by leveraging existing infrastructure and scalable fermentation expertise. CMOs provide operational flexibility to efficiently manage varying production scales and complexities. The growing adoption of advanced technologies, such as CRISPR, single-use systems, and real-time monitoring, further enhances process efficiency and product quality. Together, these factors are accelerating the expansion of the microbial fermentation CMO market.

Market Restraints

While the microbial fermentation CMO market is experiencing substantial growth, there are certain restraints that can hinder the growth of this industry. Dependence on microbial strains can cause variability in yield and quality, complicating scale-up. Further, strict regulatory requirements increase compliance burden and operational risk. Additionally, supply chain challenges for consistent raw materials can disrupt production. These factors collectively restrain the microbial fermentation CMO market.

Growth Factors

Despite the aforementioned restraints, several growth factors continue to drive the microbial fermentation CMO market forward. One notable factor is the integration of artificial intelligence and machine learning in microbial fermentation processes, which has significantly resulted in enhanced efficiency, quality, and agility across various processes. These technologies enable real-time process monitoring, predictive maintenance, and automated quality control, which reduces the downtime and minimizes variability in biopharmaceutical production. Owing to these factors, it can be anticipated that the global microbial fermentation CMO market will flourish remarkably in the foreseen future.

Microbial Fermentation CMO Market Segments

Based on the type of expression system, the market is segmented into bacterial expression systems, yeast expression systems and other expression systems.

• The bacterial expression systems sub-segment led the microbial fermentation CMO market, capturing the largest revenue share of around 65% in the current year.
• Yeast expression systems sub-segment is anticipated to show the highest growth rate of 9.6%, during the forecast period.

Based on the type of biologic manufactured, the market is segmented into recombinant proteins, antibodies, enzymes, plasmid DNA and other biologics.

• The recombinant proteins sub-segment led the microbial fermentation CMO market, capturing the largest revenue share of around 50% in the current year.
• The plasmid DNA sub-segment is anticipated to grow at an annualized rate of 10.3%, during the forecast period.

Based on the company size, the market is segmented into small companies, mid-sized companies and large and very large companies.

• The large and very large companies sub-segment led the microbial fermentation CMO market, capturing the largest revenue share of around 80% in the current year.
• The small companies sub-segment is likely to grow at an annualized rate (CAGR) of 10.3% during the forecast period.

Based on the end user, the market is segmented into pharmaceutical and biotech companies and academic and research institutes.

• Pharmaceutical and biotech companies dominated the microbial fermentation CMO market and accounted for the largest revenue share (~95%) in the current year. Further, the market in this sub segment is expected to grow at a higher annualized rate of 9.5%.
• This can be attributed to the fact that the pharmaceutical and biotech companies are the primary end users of these services.

Based on the key geographical regions, the market is segmented into North America, Europe, Asia-Pacific and Rest of the World.

• Asia-Pacific dominated the microbial fermentation CMO market and accounted for the largest revenue share (>40%) in the current year. Further, the market in Asia-Pacific is expected to grow at a higher annualized rate of 10.6%.
• This can be attributed to the fact that the number of manufacturing facilities in this region is relatively higher when compared to other regions.

Key Companies Profiled

The microbial fermentation CMO market report also includes detailed profiles of key companies (listed below) that are engaged in the microbial fermentation CMO domain:

• AbbVie
• AGC Biologics
• BioCina
• Biocon Biologics
• BIOVECTRA
• BOC Sciences
• Boehringer Ingelheim
• Eurofins
• Evonik Health Care
• FUJIFILM Biotechnologies
• KBI Biopharma
• Lonza
• Novartis
• OneSource Specialty Pharma
• Sandoz
• WuXi Biologics

You Can Download Free Sample PDF Copy of this Report at: https://www.rootsanalysis.com/reports/microbial-fermentation-cmo-market/request-sample.html

About Roots Analysis

Roots Analysis is a global leader in the market research. Having worked with over 1,500 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights. All reports provided by us are structured in a way that enables the reader to develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

Contact Details

Gaurav Chaudhary
Email: Gaurav.chaudhary@rootsanalysis.com or sales@rootsanalysis.com